Alkermes plc
Moat Score — Alkermes plc
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Alkermes holds decades of proprietary expertise and patents in extended-release and long-acting injectable drug-delivery technology, a specialized capability that underpins both its own marketed products and its royalty-generating licensing relationships. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a mid-cap specialty biopharma, Alkermes does not have a manufacturing or R&D cost advantage versus larger CNS-focused pharmaceutical competitors like Johnson & Johnson or Otsuka. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Differentiated long-acting formulations support moderate pricing versus daily oral generics, but payer formulary negotiations and competition from other long-acting injectables constrain outright pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical products do not exhibit network effects between patients or prescribers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once patients are stabilized on a particular long-acting injectable regimen, prescribers are often reluctant to switch without clear clinical reason, providing moderate prescriber and patient inertia favoring incumbents like Alkermes. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The long-acting injectable antipsychotic and addiction-treatment markets are served by only a handful of specialized manufacturers with the formulation expertise required, suggesting some efficient-scale protection against a flood of new entrants. |